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Microbeam radiation therapy (MRT) is a synchrotron-based radiotherapy
modality that uses high-intensity beams of spatially fractionated radiation to
treat tumours. The rapid evolution of MRT towards clinical trials demands
accurate treatment planning systems (TPS), as well as independent tools for the
verification of TPS calculated dose distributions in order to ensure patient safety
and treatment efficacy. Monte Carlo computer simulation represents the most
accurate method of dose calculation in patient geometries and is best suited for
the purpose of TPS verification. A Monte Carlo model of the ID17 biomedical
beamline at the European Synchrotron Radiation Facility has been developed,
including recent modifications, using the Geant4 Monte Carlo toolkit interfaced
with the SHADOW X-ray optics and ray-tracing libraries. The code was
benchmarked by simulating dose profiles in water-equivalent phantoms subject
to irradiation by broad-beam (without spatial fractionation) and microbeam
(with spatial fractionation) fields, and comparing against those calculated with
a previous model of the beamline developed using the PENELOPE code.
Validation against additional experimental dose profiles in water-equivalent
phantoms subject to broad-beam irradiation was also performed. Good
agreement between codes was observed, with the exception of out-of-field
doses and toward the field edge for larger field sizes. Microbeam results showed
good agreement between both codes and experimental results within
uncertainties. Results of the experimental validation showed agreement for
different beamline configurations. The asymmetry in the out-of-field dose
profiles due to polarization effects was also investigated, yielding important
information for the treatment planning process in MRT. This work represents
an important step in the development of a Monte Carlo-based independent
verification tool for treatment planning in MRT.
Keywords: Monte Carlo; microbeam radiation therapy; dosimetry.
1. Introduction
Microbeam radiation therapy (MRT) is an exciting develop-
ment in the treatment of cancer. It is based on the apparent
ability of healthy tissue, and inability of tumour tissue, to
withstand high doses of ionizing radiation when delivered in a
spatially fractionated manner (Slatkin et al., 1992; Bouchet et
al., 2010; Crosbie et al., 2010). MRT is currently limited to
synchrotron radiation sources and spatial fractionation is
achieved using a high-precision multi-slit collimator (MSC)
with a nominal slit width of 50 mm and a distance between slits
of 400 mm. The low divergence of the synchrotron radiation
ensures that spatial fractionation is maintained with depth in
the patient; moreover, due to the high fluence provided by
insertion devices, the irradiation takes place in a sufficiently
short time so as to avoid blurring of the spatial fractionation
caused by movement of the vasculature. The ID17 biomedical
beamline at the European Synchrotron Radiation Facility
(ESRF) has pioneered synchrotron-based MRT, with over a
decade of pre-clinical research demonstrating the feasibility of
the technique (Bräuer-Krisch et al., 2010; Bouchet et al., 2010,
2013; Schültke et al., 2008). The treatment of spontaneous
tumours in veterinary oncology patients (cats and dogs) is
imminent.
As for any radiotherapy modality, the ability to accurately
predict the distribution of dose in the patient is critical. The
most accurate method of doing so is the Monte Carlo (MC)
technique; however, due to prohibitively long computation
times, analytical techniques and simpified MC methods are
often used by treatment planning systems (TPS) to iteratively
optimize the plan. Nonetheless, MC codes are commonly used
for independent patient-specific pre-treatment verification of
TPS dose calculations (Bush et al., 2008). Such independent
calculations are required for mitigating the risk of calculation
errors, as highlighted in IAEA Technical Reports Series No.
430 (Sharpe, 2006). In addition to treatment plan verification,
MC codes are useful for optimizing the design of radiation
dosimeters used for quality assurance in radiotherapy (Lo
Meo et al., 2011; Lian et al., 2011; Rosenfeld et al., 2005).
MC calculations in MRT require careful consideration of a
number of factors which do not apply to conventional mega-
voltage radiotherapy, namely the photon beam in MRT is
highly polarized in the electron orbital plane (Hugtenburg et
al., 2010), the photon beam energy is significantly lower (in the
range 30–500 keV) (Siegbahn et al., 2006), and there is a need
for dose calculations on the micrometre scale. The latter is
required for calculation of the quantity related to the degree
of spatial fraction, the peak-to-valley dose ratio (PVDR),
which must be accurately known in order to ensure that
normal tissue tolerances are not exceeded. Additionally, it is
necessary to scan the patient vertically through the MRT
beam owing to a limited beam height, representing a time-
dependent geometry that must be accounted for in MC
calculations. To investigate the importance of these factors,
and develop reliable MC models for MRT, a considerable
amount of work has been carried out to date (Stepanek et al.,
2000; Siegbahn et al., 2006; Nettelbeck et al., 2009; Spiga et al.,
2007; De Felici et al., 2005; Hugtenburg et al., 2010). This work
has demonstrated the feasibility of MRT and enabled the
design of various beamline components. The most recent (and
detailed) model of the ESRF ID17 MRT beamline was
developed by Martinez-Rovira et al. (2012) using the PENE-
LOPE MC code and validated against a comprehensive
dataset of radiochromic film measurements in solid water
phantoms.
A TPS for MRT has been developed (Bartzsch, 2011;
Debus, 2012) in preparation for forthcoming veterinary
oncology trials, and eventual clinical trials in humans. The goal
of the current work is to develop an MC model of the MRT
beamline to be used for independent verification of TPS dose
calculations. Recent modification of the ID17 MRT beamline
resulted in a need to develop an updated MC model. We
describe herein the development of a MC model of the
beamline based on a novel interface between the Geant4 MC
toolkit and the SHADOW code, porting it to high-perfor-
mance computing facilities (HPC), benchmarking against the
previous MC model for the ID17 beamline, and validation
against dosimetry data acquired in homogeneous water-
equivalent phantoms.
2. Methods
The simulation utilizes the Geant4 MC toolkit version 4.10.00
(Agostinelli et al., 2003) interfaced with the SHADOW code
(Sanchez del Rio et al., 2011). Geant4 is a C++ MC toolkit
originally developed for high-energy physics applications, but
has since found extensive use in radiotherapy, medical imaging
and radiation protection applications. Geant4 is attractive for
use in MRT for a number of reasons: it contains photon–
electron physics models that have been validated for energies
and materials relevant to radiotherapy applications (Thiam et
al., 2008; Poon & Verhaegen, 2005); it includes an interface for
importing patient computed tomography (CT) data (Paganetti
et al., 2004); it is able to model the time-dependent geometries
of patient scanning in MRT; and it has the ability to model
complex geometries via a computer-aided design (CAD)
interface (Poole et al., 2012). Rather than continuing devel-
opment of the previous PENELOPE model, the beamline was
remodelled using Geant4 in order to take advantage of the
extensibility offered by object-oriented software design. This
allows for the use of existing classes for geometry definitions
(e.g radiation detectors), CT interfaces, customized physics
and scoring, and minimizes the time required to extend the
model by future developers. SHADOW (Sanchez del Rio et
al., 2011) is a ray-tracing and X-ray optics code developed
in the early 1980s that has since been used extensively for
simulations in beamline optics at most synchrotron facilities. It
is capable of modelling synchrotron X-ray production in the
ID17 insertion device, a task not possible with Geant4 at the
time of writing. We have interfaced the Geant4 model with the
SHADOW code via the C++ application programming inter-
face (API) of the latter. In this way, calls to the Fortran
subroutines of SHADOW are made possible from within the
C++ based Geant4 application, thereby removing the need for
the production of phase space files as done in previous
simulations (Martinez-Rovira et al., 2012).
The simulation is carried out in three stages: the first stage
models synchrotron radiation production in the insertion
device, the second transports resulting photons through the
ID17 MRT beamline, and the third performs high-accuracy
dose calculations in the vertically scanned phantom.
2.1. Stage I: synchrotron radiation production
The SHADOW code models synchrotron radiation
production in the wiggler (Lai et al., 1988) by first calculating
the trajectory followed by a single electron in the magnetic
field of the wiggler. An electron in the wiggler emits radiation
along its trajectory which is more intense in the region of
higher curvature. The code computes the number of photons
generated at each point along the trajectory and the cumu-
lated distribution function from which a MC sampling of the
photon emission along the trajectory is obtained. Once the
position of emission along the trajectory is chosen, the elec-
tron beam position and velocity are computed also taking into
account the electron beam emittance. A photon (ray) is
created for this particular electron at this position, with the
energy, divergence and electric field (polarization) calculated
research papers
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using the well known equation for synchrotron radiation
emission in a bending magnet (Green, 1976).
The parameters used to model the ID17 insertion device are
summarized in Table 1 and include: the electron beam spot-
size, horizontal and vertical divergence, and energy; and the
period, number thereof, and deflection parameter of the
wiggler. Also shown are virtual slit settings used by SHADOW
for variance reduction, defining a solid angle outside which
photons are rejected. During stage I of the simulation, the
Geant4 application makes a call to a SHADOW subroutine via
the C++ API, which subsequently returns an array of photon
phase space information containing the position, momentum
vector, polarization states and energy of each photon. This
phase space store (PSS) resides in memory for the subsequent
stage of simulation. The use of phase space files is avoided,
thereby reducing the relatively slow read–write operations to
the file system and reducing computation times.
2.2. Stage II: beamline transport
Following synchrotron radiation production in the wiggler,
the beam is transported through the ID17 MRT beamline.
There are two beamline configurations used at ID17 which are
referred to in this study. The first, referred to herein as
Condition 1, has been used for radiobiological studies and
commissioning work and is described in detail in the literature
(Martinez-Rovira et al., 2012). The second, referred to as
Condition 2, will be used for the forthcoming veterinary
oncology trials. The following description of the beamline is
made with reference to Fig. 1; distances of each component
from the source, d, are given in parentheses. The white beam
originating from the wiggler source passes through a copper
diaphragm (d = 21650 mm) with a rectangular aperture of
dimensions 24 mm 15 mm, the purpose of which is to reduce
heat load on downstream elements. The beam then traverses a
krypton gas filter (d = 26520 mm) with a dimension in the
beam direction of 2191.5 mm. This redundant filter is present
only in Condition 2; its role is to complement and protect a
downstream energy filter train (Requardt et al., 2013).
Following the gas filter are the copper primary slits (d =
29000 mm), the horizontal component of which can be
adjusted to define the horizontal limits of the irradiation field
at the patient position. The following series of carbon
(1.42 mm), aluminium (0.28 mm and 1.24 mm) and copper
(0.35 mm and 0.69 mm) filters (d = 29920 mm) provide
redundant filtering of low energies along with the aforemen-
tioned krypton filter. Either an ionization chamber (IC) or
Compton chamber (CC) beam monitor (d = 32600 mm) is then
traversed prior to exiting the in vacuo part of the beamline;
the purpose of these chambers is to monitor beam stability.
The IC (Condition 1 only) is an air-filled device of length
140.5 mm with two Be windows of thickness 0.5 mm, whereas
the CC (Condition 2 only) comprises two devices, each
containing Al plates of 0.5 mm coated on both sides with
2  104 mm of Au.
The in-air component of the MRT facility comprises a set of
tungsten slits (d = 38800 mm) which define the vertical height
of the MRT beam, with a nominal aperture height of 0.5 mm.
This is followed by the high-precision tungsten-alloy MSC (d =
research papers
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Geometry of the beamline and phantom considered in the Geant4–SHADOW simulation, showing diaphragm (DIA); krypton filter (KF) (Condition 2
only); horizontal and vertical primary slits (PS); low-energy filters (FLT); either Compton chamber (CC) (Condition 2 only) or ionization chamber (IC)
(Condition 1 only); exit windows (EXT); vertical slits (VS); multi-slit collimator (MSC); clinical ionization chamber (IC0bis); and vertically scanned
water-equivalent phantom (PHAN). Dimensions not to scale.
39300 mm) (Brauer-Krisch et al., 2009) which provides the
spatial fractionation required for MRT. The nominal slit width
of 50 mm and distance between slits of 400 mm was considered
for this work.
Following the MSC, and prior to the phantom/patient, is a
pair of parallel-plate Bragg peak chambers (PTW, Freiburg,
Germany) that are used to monitor beam fluence (d = 4 
104 mm). These are present for Condition 2 only and are
modelled in the simulation as two discs of polymethyl
methacrylate (PMMA), each of thickness 95.0 mm in the
beam direction (PTW, personal communication).
Stage II of the simulation concludes with photons traversing
a phase-space scoring plane situated prior to the patient or
phantom. Here their position, momentum, energy and polar-
ization information are stored in a second PSS for the final
stage of simulation.
2.3. Stage III: dose calculation
The beam then impinges the patient/phantom at a distance
of 40.5 m from the source. Vertical scanning of the patient is
required in order to achieve tumour coverage due to the fact
that the vertical beam dimension at the patient position
(nominal height of 520 mm) is smaller than most tumour sizes.
By exploiting the ability of Geant4 to model time-dependent
geometries (Paganetti et al., 2004), this vertical scanning is
considered in the simulation by modifying the phantom
vertical offset as a function of particle history, which is used as
a surrogate for time. Because of the phantom scanning, it is
possible to recycle the PSS and reduce the time required for
the dose calculation; however, care must be taken in order to
avoid artefacts in the dose distribution caused by the inter-
ference of events which are no longer statistically independent
(Sheikh-Bagheri & Rogers, 2002). This PSS recycling number
(Nr) was optimized based on a previously published method
(Kawrakow & Fippel, 2000), with a maximum simulation
efficiency obtained at Nr = 500. This corresponds to the PSS
being recycled every 40 mm, corresponding to 3.8% of the
beam height.
For the benchmarking simulations, a homogeneous
phantom of dimensions 200 mm  300 mm  300 mm was
modelled, composed of either water-equivalent plastic or
water. Dose deposition is then recorded in a Cartesian coor-
dinate system with a variable spatial resolution. Although
photons and electrons are transported throughout the entire
phantom, the scoring of dose only takes place in a reduced
volume of the phantom, the region of interest (ROI). Doing
so has the effect of reducing simulation times, because the
number of boundary crossings within the phantom is drasti-
cally reduced; moreover, scoring in a limited volume of the
phantom avoids the production of very large output files. The
extent of this ROI varies depending on the scenario being
simulated.
High-performance computing facilities were used to
improve simulation efficiency, with each simulation being
executed on a separate processor and seeded with a unique
seed for its respective random number generator. The mean of
all dose distributions is then calculated along with an uncer-
tainty given by the standard error within 95% confidence
limits.
2.4. Physics
The Lawrence Livermore polarized physics list included
with the Geant4 MC toolkit was used for this study. This list
models photoelectric, Rayleigh and Compton interactions for
photons. Low-energy corrections are applied to the Klein–
Nishima formula to account for electron binding. Polarization
effects for photoelectric and Compton interactions are also
considered. Multiple Couloumb scattering, ionization inter-
actions and bremsstrahlung production are modelled for
electrons. The reader is directed to the Geant4 Physics
Reference Manual for full details (GEANT4 Collaboration,
2007).
Geant4 implements a variance reduction technique known
as ‘range cuts’ in order to minimize calculation times by
reducing the number of secondaries that are tracked in elec-
tromagnetic cascades. If the residual range of a secondary
particle is less than the range cut value, the particle is not
tracked and is assumed to deposit its energy at the point of
generation, otherwise it is tracked to zero energy. A global
range cut of 10 mm was used throughout the geometry for
secondary photons and electrons. This corresponds to a cut-off
in electron energy of 61.7 keV, 71.2 keV and 14.1 keV in
copper, MSC tungsten alloy and water, respectively. In addi-
tion to range cuts, electron tracking cuts of 100 eV were
implemented in the phantom ROI.
2.5. Benchmarking: Geant4 versus PENELOPE
Owing to the difficulties of performing accurate dosimetry
in MRT with micrometre spatial resolution, reference dosi-
metry measurements are performed with a broad-beam irra-
diation, i.e. with no MSC present in the path of the beam. In
this situation, the horizontal extent of the field size is defined
by the primary horizontal slits, whereas the vertical extent is
defined by the scan limits of the goniometer upon which the
phantom is mounted. The ability of the code to accurately
calculate relative dose profiles in homogeneous phantoms
subject to irradiation by broad-beams was assessed via
benchmarking against the PENELOPE calculations of
Martinez-Rovira et al. (2012). In turn, these PENELOPE
calculations were validated against radiochromic film
measurements, full details of which can be found in the
literature (Martinez-Rovira et al., 2012). As the SHADOW
API does not presently provide the number of electrons
incident on the insertion device, a comparison of absolute
dose calculated by both codes was not possible. Instead, the
comparison was made in relative dose distributions normal-
ized to the dose at a reference depth in the phantom of 20 mm.
Three-dimensional dose distributions were calculated for
irradiation of a 200 mm  300 mm  300 mm RW3 (PTW
Freiburg, Freiburg, Germany) solid water phantom by broad-
beams of field sizes 10 mm  10 mm, 20 mm  20 mm and
30 mm  30 mm. A scoring resolution of 2 mm  0.2 mm 
research papers
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0.2 mm was used because the dose gradients are greater in the
horizontal (y) and vertical (z) directions compared with along
the beam direction (x). The comparison between Geant4–
SHADOW and PENELOPE calculations was made using the
 index, a hybrid distance-to-agreement/relative dose differ-
ence metric (Low & Dempsey, 2003). The  index is the
de facto method of comparing dose distributions in radio-
therapy (Solberg et al., 2008; Stasi et al., 2012; Pappas et al.,
2008). This test considers two dose distributions: a reference
distribution Dr(r) and an evaluation distribution De(r), where
r is a point in space. Acceptance criteria for distance-to-
agreement, d, and dose values, D, are considered. This










where D = [Dr(r)De(r)]/Dnorm and the normalization value
Dnorm can be taken either to be the global maximum in the
reference dose distribution or the local Dr(r) reference dose
value. Local normalization was chosen for the current study as
it is more sensitive to discrepancies in low-dose regions
(Bresciani et al., 2013). These are of particular importance for
MRT because the valley dose and out-of-field dose must
remain below normal tissue tolerances and therefore must be
accurately modelled.
For the evaluated distribution to agree with the reference
distribution, there must be at least one point lying within this










The  test is particularly useful for distributions with high
gradients, as is the case in MRT, for which a very small spatial
shift can result in a very high relative difference in dose.
Benchmarking against the PENELOPE code was also
carried out for microbeam irradiations of a 200 mm 300 mm
 300 mm RW3 solid water phantom in order to determine
the ability of the MC code to accurately calculate PVDRs in
water. This benchmarking was done for field sizes of 10 mm 
10 mm, 20 mm  20 mm and 30 mm  30 mm. A comparison
was made using calculated central microbeam depth-dose
distributions and central microbeam PVDRs as a function of
depth, along with radiochromic film measurements of both as
sourced from the literature (Martinez-Rovira et al., 2012). A
reduced ROI was used for scoring in order to minimize
calculation times, the dimensions of which were 200 mm 
2 mm 2 mm, with a scoring resolution of 1 mm 0.05 mm
0.1 mm.
2.6. Validation
Additional experimental validation was carried out by
simulating depth-dose distributions in a 300 mm  300 mm 
300 mm water phantom, irradiated by a 20 mm  20 mm
broad-beam field, for both Condition 1 and Condition 2.
These were calculated using a scoring resolution of 2 mm 
2 mm  2 mm and compared with those measured using a
PinPoint (PTW Freiburg, Freiburg, Germany) ionization
chamber.
2.7. Investigation of polarization effects
Due to the highly polarized nature of the MRT beam,
predominantly in the electron orbital plane of the synchro-
tron, photons undergoing Compton interactions in the
phantom/patient will be preferentially scattered in the vertical
direction. As a consequence, the out-of-field dose is greater in
the vertical direction than in the horizontal direction for the
same offset (Hugtenburg et al., 2010). The ability to predict
this out-of-field dose asymmetry is of great importance to
MRT because it will ensure that organs-at-risk are not
exposed to doses above the normal tissue tolerance. In order
to assess the accuracy of the MC model in predicting this out-
of-field dose asymmetry, the dose distribution in an RW3
phantom irradiated by a 20 mm  20 mm reference field was
simulated (Condition 1 only). Since a high spatial resolution
is not required for out-of-field dose calculations, a scoring
resolution of 2 mm  2 mm  2 mm with an extended ROI of
dimensions 150 mm 150 mm 200 mm was considered. The
calculated vertical to horizontal out-of-field dose ratios were
compared with those measured by EBT2 (Internationl
Specialty Products, Wayne, NJ, USA) radiochromic film under
the same conditions.
Preparation and analysis of EBT2 film were carried out
based on a previously published protocol (Hartmann et al.,
2010). Calibration was performed using 30 mm  30 mm
pieces from a single sheet placed at a depth of 20 mm in a RW3
solid water phantom and irradiated with a 20 mm  20 mm
broad-beam to doses of 30, 50, 75, 100, 200 and 300 Gy.
Measurement pieces, taken from the same sheet and with
dimensions of approximately 100 mm  50 mm, were placed
at depths of 20 mm and 40 mm in a solid water phantom and
irradiated with a 20 mm  20 mm field. The total dose deliv-
ered at the reference depth was approximately 40 kGy; this
was required to ensure that the out-of-field dose fell within the
calibration range. Readout was performed six days post-irra-
diation using an EPSON Perfection V700 scanner, 72 d.p.i.
resolution (equivalent spatial resolution of 0.35 mm) and 48-
bit colour. ImageJ was then used to isolate the red channel of
the images, and export these pixel value images as text files.
An automated Python script was subsequently used to apply
the dose calibration and sample the out-of-field dose at
distances in the vertical and horizontal direction. This dose
was calculated using the average pixel value over a 1 mm2 area
and applying the calibration curve. Uncertainties were calcu-
lated using the standard error of these readings, within 95%
confidence intervals. The experiment was repeated and results
averaged over the two sets of measurements.
3. Results
Fig. 2 shows a plot of Geant4 and PENELOPE simulated
depth-dose profiles in an RW3 water-equivalent phantom
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irradiated by broad-beams of given field sizes. The total
simulation time for each field was approximately 5 h running
in parallel on one-hundred 2.67 GHz cores [Intel(R) Xeon(R)
X5650 CPU]. The percentage of total time spent for stages I,
II and III were 2%, 2% and 96%, respectively. Doses were
normalized to a depth of 20 mm. Also shown are  indices
for distance-to-agreement/relative dose difference criteria of
3 mm/3%; points below a value of unity indicate agreement
between the two codes. There was excellent agreement, with
97%, 99% and 94% of points passing the  test within a depth
of 150 mm for 10 mm  10 mm, 20 mm  20 mm and 30 mm
 30 mm fields, respectively.
Fig. 3 presents the corresponding horizontal dose profiles.
For all field sizes the out-of field dose differed by more than
0.3 mm/3% between the two codes, with Geant4 results lying
closer to the experimentally measured values. For the in-field
dose component, the results for the 20 mm  20 mm and
30 mm  30 mm broad-beam showed significant difference
between Geant4 and PENELOPE toward the edge of the
field; once more, Geant4 results were closer to experimental
values. Although both Geant4 and PENELOPE simulations
account for the polarization of the source, the latter used an
approximate source model for which position, direction and
energy of photons were sampled from parametric probability
distributions based on phase space files scored prior to the
phantom. These distributions included approximations such as
sampling the horizontal position of photons with a uniform
probability over the field size (Martinez-Rovira et al., 2012). In
order to investigate whether such assumptions were the cause
of the discrepancy observed in the current study, identical
assumptions were made in the Geant4–SHADOW code.
Results are shown in Fig. 4, with agreement in the horizontal
dose profiles for the 30 mm  30 mm field size once these
approximations were implemented.
Agreement was obtained in-field for the vertical profiles
given in Fig. 5, with disagreement in out-of-field doses.
Contrary to the horizontal profiles, PENELOPE results were
closer to the film measurements than Geant4 results for the
out-of-field doses.
Fig. 6 presents a sample of Geant4-calculated horizontal
dose profiles for MRT microbeam irradiation of a water-
equivalent phantom by a field size of 10 mm  10 mm, with
research papers
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Figure 3
Comparison between Geant4-simulated, PENELOPE-simulated and experimentally measured horizontal dose profiles at 20 mm depth in an RW3
water-equivalent phantom irradiated by given broad-beam field sizes. The  indices for criteria of 0.3 mm/3% are shown as crosses.
Figure 2
Comparison between Geant4- and PENELOPE-calculated depth-dose profiles for broad-beam irradiation of an RW3 water-equivalent phantom for
given field sizes. The  indices for criteria of 3 mm/3% are shown as crosses.
results normalized to the peak dose at 3 mm. The total
simulation time for all fields was approximately 10 h running
in parallel on one-hundred 2.67 GHz cores [Intel(R) Xeon(R)
CPU X5650]. The effect of the ROI on computation time was
marked for this case, with a 34-fold decrease compared with
the case of scoring in the entire phantom. The decrease in
peak dose with depth in the phantom can be seen, as can the
build-up of valley dose between 3 mm and 20 mm depth,
followed by the reduction with depth in accordance with
attenuation of the primary beam. Fig. 7 presents central
microbeam peak depth-dose (PDD) distributions for various
field sizes as calculated by Geant4 and PENELOPE, along
with experimental measurements obtained with radiochromic
film. Simulation and experimental results all agreed within
uncertainties of the experimental results. However, relative
experimental uncertainties were up to 14.7%, highlighting the
need for improvement of the precision of dosimetry in MRT.
The valley depth-dose (VDD) for the same simulation is
shown in Fig. 8. The valley dose initially increased with depth,
followed by reduction with depth in accordance with
attenuation of the primary beam. Moreover, the valley dose
increased with an increase in field size due to the concomitant
increase in scattered photons in the phantom. Both codes
agreed with each other, and with the experimental data, within
uncertainties.
Results of the corresponding central microbeam PVDRs
are given in Fig. 9. The PVDR decreased with depth owing to
the increase in valley dose cause by photons scattered out of
the primary beam. At the same depth, the PVDR decreased
with an increase in field size due to the increased contribution
from scattered photons. Both codes agreed with experimental
measurements within the experimental uncertainty (up to
28% for the 10 mm  10 mm field size). Once more, higher-
precision dosimetry is required to conclusively determine
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Figure 4
Comparison between Geant4- and PENELOPE-simulated horizontal
dose profiles at 20 mm depth in an RW3 water-equivalent phantom
irradiated by a 30 mm  30 mm broad-beam. Geant4 results were
obtained with the same source parameterization used in the PENELOPE
beam model.
Figure 5
Comparison between Geant4-simulated, PENELOPE-simulated and experimentally measured vertical dose profiles at 20 mm depth in an RW3 water-
equivalent phantom irradiated by given broad-beam field sizes. The  indices for criteria of 0.3 mm/3% are shown as crosses.
Figure 6
Horizontal dose profiles of a microbeam array at given depths in a water-
equivalent phantom irradiated by a 30 mm  30 mm field; calculated by
the Geant4–SHADOW code.
which of the two simulations was more accurate in calculating
PVDRs.
Fig. 10 shows depth-dose profiles in a water phantom
subject to irradiation by the 20 mm  20 mm broad-beam,
normalized to dose at 20 mm depth. Slight beam-hardening
was observed for Condition 1 owing to greater attenuation of
the low-energy component by the additional beam-monitoring
elements, namely the CC and Bragg peak chambers. Geant4-
simulated and experimental results agreed within 2.3% for
both Condition 1 and Condition 2.
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Figure 7
Geant4- and PENELOPE-calculated and experimental depth-dose profiles of the central microbeam for microbeam irradiation of an RW3 water-
equivalent phantom for given field sizes.
Figure 8
Geant4- and PENELOPE-calculated and experimental valley depth-dose profiles of the central microbeam for irradiation of a water-equivalent
phantom at given field sizes.
Figure 9
Geant4- and PENELOPE-calculated and experimental PVDRs of the central microbeam for microbeam irradiation of an RW3 water-equivalent
phantom for given field sizes.
The asymmetry of out-of-field doses in the vertical and
horizontal direction is presented in Fig. 11, as calculated by
Geant4 and measured using EBT2 radiochromic film. At a
given depth, the dose asymmetry increased with increasing
distance from the field edge. With increasing depth in the
phantom, the asymmetry reduced, presumably due to the
increasing proportion of scattered photons having randomly
oriented polarization vectors. The relative differences
between experiment and simulation (relative to simulation)
were within 3.2% at 20 mm depth and 11.5% at 40 mm depth.
4. Discussion
Good agreement was obtained between the Geant4–
SHADOW and PENELOPE simulations of broad-beam
irradiation of an RW3 phantom when comparing depth-dose
profiles within a depth of 150 mm, as well as horizontal and
vertical dose profiles. For larger field sizes, there was discre-
pancy between codes toward the edge of the field for hori-
zontal profiles, with Geant4 results lying closer to film
measurements. This discrepancy was shown to be due to the
parameterized source model used in the PENELOPE simu-
lation, demonstrating the importance of detailed MC source
modelling in MRT when high-accuracy dose calculations are
required.
Additional experimental validation of the Geant4–
SHADOW code was carried out by simulating depth-dose
profiles in a water phantom and comparing with those
measured with a calibrated IC under different beamline
configurations, for which agreement within 2.3% was
observed. This agreement confirms the ability of the code to
accurately predict relative depth-dose distributions in homo-
geneous phantoms subject to irradiation with the MRT
broad-beam.
Notwithstanding the high uncertainties of the film
measurements of central microbeam PDDs and PVDRs,
agreement was seen between both codes and experimental
results. The lack of precision in experimental data prevents a
definitive assessment of which code is more accurate in the
calculation of microbeam parameters, once again highlighting
the need for higher precision dosimetry in MRT. Silicon
microstrip detectors offer the ability to provide high-precision
measurements of valley doses (Petasecca et al., 2012);
however, energy dependence at low energies is pronounced
(Cheung et al., 2009). This energy dependence could lead to an
over-response in valley dose due to the dominance of lower-
energy photons scattered out of the primary beam (Siegbahn
et al., 2006). Such an artefact could be mitigated by incor-
porating the detector geometry and composition directly into
the MC model (Rosenfeld et al., 2006). A direct comparison
between PVDR values obtained in the present study and
those published in the literature is difficult owing to signifi-
cantly different beam conditions (different beam energies,
field sizes and phantom materials) used for each.
The accuracy of the Geant4–SHADOW code in predicting
out-of-field dose asymmetry in MRT was also determined. The
importance of polarization has been the topic of discussion
in the MRT research community; its effect was found to be
negligible at the centre of a 30 mm  30 mm microbeam field,
yet increasing to 16% at the field edge for a 200 keV mono-
energetic beam (De Felici et al., 2005). In a separate study
(Hugtenburg et al., 2010), clinically relevant dose volume
histograms were calculated for an organ-at-risk in a hypo-
thetical MRT treatment, in which case the secondary scatter
was found to have a significiant effect. The current findings
support the notion that the effect of beam polarization on out-
of-field doses must be taken into consideration in any TPS
system for MRT. Based on these results, ignoring asymmetry
in the out-of-field dose profiles could lead to errors of up to
150%. Since an intended application is for paediatric patients
suffering glioblastomas, the importance in the context of
mitigating the risk of secondary malignancies is amplified
(Newhauser & Durante, 2011). The present study has
demonstrated the ability of Geant4 to predict the dose
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Figure 10
Percentage depth-dose as calculated by Geant4–SHADOW code and
measured by a PinPoint IC in a water phantom irradiated by a 20 mm 
20 mm reference field for both Condition 1 and Condition 2 beamline
configurations.
Figure 11
The ratio of vertical-to-horizontal dose as a function of distance from the
beam axis for depths of 20 mm and 40 mm in an RW3 water-equivalent
phantom; calculated by the Geant4–SHADOW code and measured using
EBT2 radiochromic film.
asymmetry resulting from beam polarization, albeit with
limited precision and accuracy. The challenge remains to
develop a more precise dosimetry system in conjunction with
refining the theoretical models of Compton scattering present
in Geant4 to obtain very high accuracy in out-of-field dose
calculations.
The deflection parameter used in the current work (K =
19.5) is markedly lower than that used in the work of
Martinez-Rovira et al. (2012) (K = 22.3). The deflection
parameter of ID17 is based on a parameterized fit of peak
magnetic (Bo) field versus wiggler gap, where the magnetic
field is assumed to be sinusoidally varying along the length of
the wiggler. In reality, the wiggler comprises a total of 21 poles
including 17 internal poles with a peak field Bo (described
by the aforementioned parameterized formula), two inter-
mediate poles at 0.86Bo and two extremity poles at 0.53Bo
(Chavanne, 1998). This uncertainty in the deflection para-
meter supports its use as a quasi-free parameter that may be
tuned in order to obtain agreement between experimental
results and the Geant4–SHADOW code.
The clinical implications of this research lie in the need for
independent pre-treatment plan verification tools in MRT (as
for any radiotherapy modality) as recommended by the IAEA
Technical Report Series No. 430 (Sharpe, 2006). MC repre-
sents the most accurate method of calculating dose in patient
geometries, and we have developed a tool for dose calcula-
tions in homogeneous phantoms. This tool has been bench-
marked against an MC model of the previous beamline
configuration and validated against experimental data
acquired with both beamline Condition 1 and 2. It enables
event-by-event simulation from photon production in the
wiggler through to dose deposition in the phantom, within
time constraints deemed suitable for a radiotherapy modality
in the pre-clinical stage of development. In its current form,
the simulation will be able to provide accurate dose estimates
for radiobiological experiments performed on the beamline. It
may also be used in the optimization of radiation detector
design by incorporating relevant composition and geometry
into the simulation (Othman et al., 2010; Lian et al., 2011).
Prior to use as a TPS verification tool, this application will
need to be validated by simulating experimental data acquired
in heterogenous phantoms using the CT interface of Geant4.
The increase in simulation time is not expected to be exces-
sive. Dose calculations in the CT dataset will involve a similar
number of scoring voxels as the current simulations. It is
expected that simulation times of 10 h running on 100 cores of
a high-performance computing facility will provide acceptable
statistics. This will be acceptable for the purpose of pre-
treatment plan verification in the early clinical stages of MRT,
for which patient turnover will be low. Experimental valida-
tion will be carried out by irradiation of film, silicon devices
and ionization chambers embedded in an anthropomorphic
phantom. The current study used normalized dose distribu-
tions to benchmark and validate the code; future studies will
be conducted to determine the ability of the code to determine
absolute dose values in MRT. Moreover, future studies will
compare full two-dimensional and three-dimensional dose
distributions of microbeam irradiations, rather than the one-
dimensional profiles used in the present study.
Comparison of dose distributions was performed using the
 index method. Use of the  index for comparing dose
distributions in MRT is unprecedented, with previous authors
implementing a variety of metrics. Martinez-Rovira et al.
(2012) implemented a piece-wise relative dose difference
metric with tolerance varying depending on whether the dose
points are determined to be in-field, in the beam penumbra, or
out of the treatment field (Venselaar et al., 2001). Although all
such metrics are useful in validating dosimetry calculations in
phantoms, their clinical relevance has recently been brought
into question (Nelms et al., 2011; Stasi et al., 2012); i.e. the
ability of a dose calculation engine to predict one-dimensional
and two-dimensional dose distributions in phantoms has little
correlation with its ability to accurately predict dose to
anatomical structures. A more clinically relevant metric, such
as a dose volume histogram for target volumes and organs at
risk, should be used to perform routine quality assurance of
patient treatment plans.
5. Conclusions
We have developed an up-to-date MC model of the ID17
MRT beamline based on a novel interface between the Geant4
toolkit and SHADOW code, allowing for event-by-event
modelling from wiggler to phantom. The MC code was ported
to HPC facilities and benchmarked by comparison with
PENELOPE simulations. Additional experimental validation
of the code was carried out via comparison against IC
measurements in a water phantom, as well as a study of the
out-of-field dose asymmetry in a water-equivalent phantom
subject to broad-beam irradiation. This interface removes the
need for parameterized source models based on phase space
files, leading to more accurate dose calculations. The time-
dependent geometry of the application will allow for the
simulation of novel time-resolved dosimetry systems and
patient scanning in MRT. The accuracy of Geant4 in the
calculation of dose in MRT was demonstrated, paving the way
for the creation of an independent treatment plan verification
tool.
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